Thomas A. MCCOURT - 16 May 2025 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
Chief Executive Officer, Director
Signature
/s/ Brian Tessler, Attorney-in-Fact
Issuer symbol
IRWD
Transactions as of
16 May 2025
Net transactions value
-$7,745
Form type
4
Filing time
20 May 2025, 16:14:00 UTC
Previous filing
12 Feb 2025
Next filing
09 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MCCOURT Thomas A Chief Executive Officer, Director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON /s/ Brian Tessler, Attorney-in-Fact 20 May 2025 0001478448

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Sale $7,745 -13,353 -1.2% $0.5800 1,147,281 16 May 2025 Direct F1
transaction IRWD Class A Common Stock Award $0 +540,000 +47% $0.000000 1,687,281 20 May 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person.
F2 The restricted stock unit award, granted as an annual performance award, vests as to 33.33% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.